blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1831365

EP1831365 - USE OF RNA TRANS-SPLICING FOR ANTIBODY GENE TRANSFER AND ANTIBODY POLYPEPTIDE PRODUCTION [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  13.06.2014
Database last updated on 24.08.2024
Most recent event   Tooltip24.07.2015Lapse of the patent in a contracting state
New state(s): BG, HU, LU		published on 26.08.2015  [2015/35]
Applicant(s)For all designated states
VIRxSYS Corporation
200 Perry Parkway Suite 1A
Gaithersburg, MD 20877 / US
[2013/32]
Former [2008/03]For all designated states
VIRxSYS Corporation
200 Perry Parkway, Suite 1A Gaithersburg
Maryland 20877 / US
Former [2007/37]For all designated states
Intronn, Inc.
9700 Great Seneca Highway
Rockville, MD 20850 / US
Inventor(s)01 / MCGARRITY, Gerard, J.
105 Leekes Lot Way
Gaithersburg, MD 20878 / US
02 / PUTTARAJU, Madaiah
12115 Stardrift Drive
Germantown, MD 20876 / US
03 / GARCIA-BLANCO, Mariano, A.
12 Saderling Court
Durham, NC 27713 / US
 [2007/37]
Representative(s)Lord, Hilton David, et al
Marks & Clerk LLP
90 Long Acre
London WC2E 9RA / GB
[N/P]
Former [2013/32]Lord, Hilton David, et al
Marks & Clerk LLP
90 Long Acre
London
WC2E 9RA / GB
Former [2011/43]Lord, Hilton David, et al
Marks & Clerk LLP 90 Long Acre London
WC2E 9RA / GB
Former [2009/31]Irvine, Jonquil Claire, et al
Marks & Clerk LLP 4220 Nash Court Oxford Business Park South Oxford
OX4 2RU / GB
Former [2007/37]Lucas, Phillip Brian
Lucas & Co. 135 Westhall Road
Warlingham, Surrey CR6 9HJ / GB
Application number, filing date05815099.607.10.2005
[2007/37]
WO2005US36215
Priority number, dateUS20040617012P08.10.2004         Original published format: US 617012 P
US20040629821P19.11.2004         Original published format: US 629821 P
[2007/37]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2006083331
Date:10.08.2006
Language:EN
[2006/32]
Type: A2 Application without search report 
No.:EP1831365
Date:12.09.2007
Language:EN
The application published by WIPO in one of the EPO official languages on 10.08.2006 takes the place of the publication of the European patent application.
[2007/37]
Type: B1 Patent specification 
No.:EP1831365
Date:07.08.2013
Language:EN
[2013/32]
Search report(s)International search report - published on:EP26.07.2007
ClassificationIPC:C12N15/10
[2007/37]
CPC:
C07K16/084 (EP,US); A61P19/02 (EP); A61P29/00 (EP);
A61P31/04 (EP); A61P35/00 (EP); A61P37/06 (EP);
C07K16/00 (EP,US); C12N15/1027 (EP,US); A61K2039/505 (EP,US);
A61K48/00 (EP,US); C07K2317/622 (EP,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2007/37]
TitleGerman:VERWENDUNG VON RNS TRANS-SPLICING ZUM ANTIKÖRPER GEN TRANSFER UND ZUR ANTIKÖRPERHERSTELLUNG[2007/37]
English:USE OF RNA TRANS-SPLICING FOR ANTIBODY GENE TRANSFER AND ANTIBODY POLYPEPTIDE PRODUCTION[2007/37]
French:UTILISATION D'UN TRANS-EPISSAGE D'ARN POUR LE TRANSFERT GENIQUE D'ANTICORPS ET LA PRODUCTION POLYPEPTIDIQUE D'ANTICORPS[2007/37]
Entry into regional phase27.03.2007National basic fee paid 
27.03.2007Designation fee(s) paid 
27.03.2007Examination fee paid 
Examination procedure27.03.2007Examination requested  [2007/37]
21.01.2008Despatch of a communication from the examining division (Time limit: M08)
01.08.2008Reply to a communication from the examining division
09.08.2011Despatch of a communication from the examining division (Time limit: M06)
27.12.2011Reply to a communication from the examining division
16.01.2012Despatch of a communication from the examining division (Time limit: M06)
10.07.2012Reply to a communication from the examining division
15.02.2013Communication of intention to grant the patent
24.06.2013Fee for grant paid
24.06.2013Fee for publishing/printing paid
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  21.01.2008
Opposition(s)08.05.2014No opposition filed within time limit [2014/29]
Fees paidRenewal fee
23.10.2007Renewal fee patent year 03
31.03.2008Renewal fee patent year 04
13.10.2009Renewal fee patent year 05
12.10.2010Renewal fee patent year 06
11.10.2011Renewal fee patent year 07
25.10.2012Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU07.10.2005
AT07.08.2013
BE07.08.2013
BG07.08.2013
CY07.08.2013
CZ07.08.2013
DK07.08.2013
EE07.08.2013
ES07.08.2013
FI07.08.2013
IT07.08.2013
LT07.08.2013
LV07.08.2013
MC07.08.2013
NL07.08.2013
PL07.08.2013
RO07.08.2013
SE07.08.2013
SI07.08.2013
SK07.08.2013
TR07.08.2013
IE07.10.2013
LU07.10.2013
CH31.10.2013
FR31.10.2013
LI31.10.2013
GB07.11.2013
GR08.11.2013
IS07.12.2013
PT09.12.2013
DE01.05.2014
[2015/34]
Former [2015/32]AT07.08.2013
BE07.08.2013
CY07.08.2013
CZ07.08.2013
DK07.08.2013
EE07.08.2013
ES07.08.2013
FI07.08.2013
IT07.08.2013
LT07.08.2013
LV07.08.2013
MC07.08.2013
NL07.08.2013
PL07.08.2013
RO07.08.2013
SE07.08.2013
SI07.08.2013
SK07.08.2013
TR07.08.2013
IE07.10.2013
CH31.10.2013
FR31.10.2013
LI31.10.2013
GB07.11.2013
GR08.11.2013
IS07.12.2013
PT09.12.2013
DE01.05.2014
Former [2014/51]AT07.08.2013
BE07.08.2013
CY07.08.2013
CZ07.08.2013
DK07.08.2013
EE07.08.2013
ES07.08.2013
FI07.08.2013
IT07.08.2013
LT07.08.2013
LV07.08.2013
MC07.08.2013
NL07.08.2013
PL07.08.2013
RO07.08.2013
SE07.08.2013
SI07.08.2013
SK07.08.2013
IE07.10.2013
CH31.10.2013
FR31.10.2013
LI31.10.2013
GB07.11.2013
GR08.11.2013
IS07.12.2013
PT09.12.2013
DE01.05.2014
Former [2014/48]AT07.08.2013
BE07.08.2013
CY07.08.2013
CZ07.08.2013
DK07.08.2013
EE07.08.2013
ES07.08.2013
FI07.08.2013
IT07.08.2013
LT07.08.2013
LV07.08.2013
MC07.08.2013
NL07.08.2013
PL07.08.2013
RO07.08.2013
SE07.08.2013
SI07.08.2013
SK07.08.2013
IE07.10.2013
CH31.10.2013
FR31.10.2013
LI31.10.2013
GR08.11.2013
IS07.12.2013
PT09.12.2013
DE01.05.2014
Former [2014/37]AT07.08.2013
BE07.08.2013
CY07.08.2013
CZ07.08.2013
DK07.08.2013
EE07.08.2013
ES07.08.2013
FI07.08.2013
IT07.08.2013
LT07.08.2013
LV07.08.2013
MC07.08.2013
NL07.08.2013
PL07.08.2013
RO07.08.2013
SE07.08.2013
SI07.08.2013
SK07.08.2013
CH31.10.2013
FR31.10.2013
LI31.10.2013
GR08.11.2013
IS07.12.2013
PT09.12.2013
DE01.05.2014
Former [2014/34]AT07.08.2013
BE07.08.2013
CY07.08.2013
CZ07.08.2013
DK07.08.2013
EE07.08.2013
ES07.08.2013
FI07.08.2013
IT07.08.2013
LT07.08.2013
LV07.08.2013
MC07.08.2013
NL07.08.2013
PL07.08.2013
RO07.08.2013
SE07.08.2013
SI07.08.2013
SK07.08.2013
CH31.10.2013
LI31.10.2013
GR08.11.2013
IS07.12.2013
PT09.12.2013
Former [2014/25]AT07.08.2013
BE07.08.2013
CY07.08.2013
CZ07.08.2013
DK07.08.2013
EE07.08.2013
ES07.08.2013
FI07.08.2013
IT07.08.2013
LT07.08.2013
LV07.08.2013
MC07.08.2013
NL07.08.2013
PL07.08.2013
RO07.08.2013
SE07.08.2013
SI07.08.2013
SK07.08.2013
GR08.11.2013
IS07.12.2013
PT09.12.2013
Former [2014/24]AT07.08.2013
BE07.08.2013
CY07.08.2013
CZ07.08.2013
DK07.08.2013
EE07.08.2013
ES07.08.2013
FI07.08.2013
IT07.08.2013
LT07.08.2013
LV07.08.2013
NL07.08.2013
PL07.08.2013
RO07.08.2013
SE07.08.2013
SI07.08.2013
SK07.08.2013
GR08.11.2013
IS07.12.2013
PT09.12.2013
Former [2014/23]AT07.08.2013
BE07.08.2013
CY07.08.2013
CZ07.08.2013
DK07.08.2013
EE07.08.2013
ES07.08.2013
FI07.08.2013
LT07.08.2013
LV07.08.2013
NL07.08.2013
PL07.08.2013
RO07.08.2013
SE07.08.2013
SI07.08.2013
SK07.08.2013
GR08.11.2013
IS07.12.2013
PT09.12.2013
Former [2014/22]AT07.08.2013
BE07.08.2013
CY07.08.2013
DK07.08.2013
ES07.08.2013
FI07.08.2013
LT07.08.2013
LV07.08.2013
NL07.08.2013
PL07.08.2013
RO07.08.2013
SE07.08.2013
SI07.08.2013
GR08.11.2013
IS07.12.2013
PT09.12.2013
Former [2014/21]AT07.08.2013
BE07.08.2013
CY07.08.2013
DK07.08.2013
ES07.08.2013
FI07.08.2013
LT07.08.2013
LV07.08.2013
NL07.08.2013
PL07.08.2013
SE07.08.2013
SI07.08.2013
GR08.11.2013
IS07.12.2013
PT09.12.2013
Former [2014/18]AT07.08.2013
BE07.08.2013
CY07.08.2013
ES07.08.2013
FI07.08.2013
LT07.08.2013
LV07.08.2013
NL07.08.2013
PL07.08.2013
SE07.08.2013
SI07.08.2013
GR08.11.2013
IS07.12.2013
PT09.12.2013
Former [2014/14]CY24.07.2013
AT07.08.2013
BE07.08.2013
ES07.08.2013
FI07.08.2013
LT07.08.2013
LV07.08.2013
NL07.08.2013
PL07.08.2013
SE07.08.2013
SI07.08.2013
GR08.11.2013
IS07.12.2013
PT09.12.2013
Former [2014/12]CY24.07.2013
AT07.08.2013
ES07.08.2013
FI07.08.2013
LT07.08.2013
LV07.08.2013
PL07.08.2013
SE07.08.2013
SI07.08.2013
GR08.11.2013
IS07.12.2013
PT09.12.2013
Former [2014/11]CY24.07.2013
AT07.08.2013
FI07.08.2013
LT07.08.2013
PL07.08.2013
SE07.08.2013
IS07.12.2013
PT09.12.2013
Former [2014/10]CY24.07.2013
AT07.08.2013
LT07.08.2013
SE07.08.2013
IS07.12.2013
PT09.12.2013
Former [2014/09]AT07.08.2013
LT07.08.2013
SE07.08.2013
PT09.12.2013
Former [2014/08]LT07.08.2013
PT09.12.2013
Cited inInternational search[XY]WO03072739  (INTRONN INC [US], et al) [X] 1,4-6,14,17-19,27,30-32,40,44-46 * pages 8-11; figure 1; example -; claims 1,9-13 * * same passages * [Y] 1-53;
 [XY]  - SCHLESINGER J ET AL, "In-cell generation of antibody single-chain Fv transcripts by targeted RNA trans-splicing", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, (200311), vol. 282, no. 1-2, ISSN 0022-1759, pages 175 - 186, XP004471812 [X] 1,7-9,14,20-22,27,33-35,40,41,47-49 * page 177, column R, paragraph L - page 182, column R, paragraph 1; figure 1 * * same passages * [Y] 1-53

DOI:   http://dx.doi.org/10.1016/j.jim.2003.08.006
 [Y]  - MANSFIELD S GARY ET AL, "RNA repair using spliceosome-mediated RNA trans-splicing.", TRENDS IN MOLECULAR MEDICINE. JUN 2004, (200406), vol. 10, no. 6, ISSN 1471-4914, pages 263 - 268, XP002393373 [Y] 1-53 * page 265 - page 266; figures 1-5 *

DOI:   http://dx.doi.org/10.1016/j.molmed.2004.04.007
 [Y]  - PERGOLIZZI R G ET AL, "Genetic medicine at the RNA level: modifications of the genetic repertoire for therapeutic purposes by pre-mRNA trans-splicing", COMPTES RENDUS - BIOLOGIES, ELSEVIER, PARIS, FR, (200408), vol. 327, no. 8, ISSN 1631-0691, pages 695 - 709, XP004561828 [Y] 1-53 * page 700 - page 702; figures 1-4 *

DOI:   http://dx.doi.org/10.1016/j.crvi.2004.05.008
 [PY]  - PUTTARAJU ET AL, "1113. Spliceosome Mediated RNA Trans-Splicing (SMaRT(TM)) Strategy To Increase the Production of Human Apolipoprotein (ApoA1)", MOLECULAR THERAPY, ACADEMIC PRESS, SAN DIEGO, CA,, US, (20050815), vol. 11, ISSN 1525-0016, page 429, XP005016452 [PY] 1-53 * abstract *
by applicantWO03072739
    - SCHLESINGER ET AL., J IMMUNOL METHODS, (2003), vol. 282, no. 1-2, pages 175 - 86
    - MANSFIELD ET AL., TRENDS MOL MED, (2004), vol. 10, no. 6, pages 263 - 268
    - PERGOLIZZI ET AL., C R BIOL., (2004), vol. 327, no. 8, pages 695 - 709
    - BREKKE; SANDLIE, "Therapeutic antibodies for human diseases at the dawn of the twenty first century", NATURE REVIEWS DRUG DISCOVERY, (2003), vol. 2, pages 52 - 62
    - ANDERSON; ANDERSON, MOLEC. CELL PROTEOMICS, (2002), vol. 1, page 845
    - UHLMANN ET AL., CHEM. REV., (1990), vol. 90, pages 543 - 584
    - SCHNEIDER ET AL., TETRAHEDRON LETT., (1990), vol. 31, page 335
    - STEIN, C. A. ET AL., NUCLEIC ACIDS RES., (1988), vol. 16, pages 3209 - 3221
    - COSSTICK, R. ET AL., TETRAHEDRON LETTERS, (1989), vol. 30, pages 4693 - 4696
    - BRILL, W. K.-D. ET AL., J. AMER. CHEM. SOC., (1989), vol. 111, pages 2321 - 2322
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.